Jonathan Zalevsky, Ph.D.

Jonathan Zalevsky, Ph.D., currently holds the position of Chief Research & Development Officer. He joined the company in 2015 and was appointed as Chief Scientific Officer in 2017, a role he held until his current appointment. Prior to joining his current company, Dr. Zalevsky worked at Takeda Pharmaceuticals where he was the Global Vice President and Head of the Inflammation Drug Discovery Unit. His earlier career includes a significant tenure at Xencor, where he was instrumental in overseeing the discovery and development of the company’s first four clinical-stage assets. Dr. Zalevsky earned his Ph.D. in Biochemistry from the Tetrad Program at the University of California, San Francisco, after completing dual B.S. degrees in Biochemistry and Molecular, Cellular, and Developmental Biology at the University of Colorado at Boulder.